← Back to Search

Radiation

Adaptive Radiation for Abdominopelvic Cancer

Phase 1

Recruiting

Led By Joshua Meyer, MD

Research Sponsored by Fox Chase Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

Study Summary

This trial tests a new radiation therapy for cancer in the abdomen/pelvis to give higher doses with fewer side effects than current treatments.

Who is the study for?

This trial is for adults over 18 with metastatic cancer in the abdomen or pelvis, who have at least one lesion not treated by radiation or growing. They must have acceptable liver and kidney function, a certain level of blood cells, an ECOG performance status of 0 or 1, and be expected to live at least another year. Pregnant women, those with too many metastases (6+), prior radiotherapy on target lesions, uncontrolled illnesses, or severe toxicity from past treatments are excluded.Check my eligibility

What is being tested?

The trial tests adaptive stereotactic body radiation therapy (SBRT) for patients with abdominopelvic metastases. It's a Phase I study aiming to increase the dose while keeping serious side effects under control. The goal is local tumor control or symptom relief using advanced SBRT that adapts to changes during treatment.See study design

What are the potential side effects?

Potential side effects include grade 3+ toxicities which could involve damage to nearby organs due to high-dose radiation such as gastrointestinal issues like ulcers or bleeding; fatigue; skin reactions; and possibly other organ-specific complications depending on the area being treated.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Adaptive Stereotactic Body RadiationExperimental Treatment1 Intervention

Simulation and treatment to be performed over 3-4 weeks per dose escalation

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Fox Chase Cancer CenterLead Sponsor

227 Previous Clinical Trials

37,508 Total Patients Enrolled

Joshua Meyer, MDPrincipal InvestigatorFox Chase Cancer Center

6 Previous Clinical Trials

193 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Adaptive Stereotactic Body Radiation sanctioned by the Federal Drug Administration?

"As this is an exploratory trial with limited evidence showing its efficacy and safety, the Adaptive Stereotactic Body Radiation was assigned a score of 1."

Answered by AI

How many participants is the clinical trial currently accommodating?

"Yes, according to the information hosted on clinicaltrials.gov this medical study is still open for recruitment. It was first posted on August 1st 2023 and last updated September 5th 2023 with a requirement of 30 participants from one centre."

Answered by AI

Are there presently any openings in this clinical trial?

"Evidenced by clinicaltrials.gov, this project is now open to recruitment and was initially published on the 1st of August 2023 with its last modification having taken place on September 5th 2023."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Adaptive Radiation for Abdominopelvic Metastases

2023. "Adaptive Radiation for Abdominopelvic Metastases". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05880667.